Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 899 | 147 | 715 |
| Samples | 511 | 109 | 388 |
| Peptides | 367 | 65 | 308 |
Function
GRM2 · Glutamate metabotropic receptor 2
L-glutamate is the major excitatory neurotransmitter in the central nervous system and activates both ionotropic and metabotropic glutamate receptors. Glutamatergic neurotransmission is involved in most aspects of normal brain function and can be perturbed in many neuropathologic conditions. The metabotropic glutamate receptors are a family of G protein-coupled receptors, that have been divided into 3 groups on the basis of sequence homology, putative signal transduction mechanisms, and pharmacologic properties. Group I includes GRM1 and GRM5 and these receptors have been shown to activate phospholipase C. Group II includes GRM2 and GRM3 while Group III includes GRM4, GRM6, GRM7 and GRM8. Group II and III receptors are linked to the inhibition of the cyclic AMP cascade but differ in their agonist selectivities. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2017].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 358 amino-acid changes on canonical ENST00000395052 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in GRM2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in GRM2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 7/40 18% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| Chordoma | 1/7 14% | 0/13 0% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Colorectal Carcinoma | 19/143 13% | 99/3239 3% |
| Melanoma | 15/210 7% | 57/1899 3% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Endometrial Carcinoma | 5/42 12% | 15/612 2% |
| Gastric Carcinoma | 3/74 4% | 48/1809 3% |
| Non-Small Cell Lung Carcinoma | 16/304 5% | 20/1390 1% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Hodgkins Lymphoma | 1/16 6% | 1/122 1% |
| Cervical Carcinoma | 3/35 9% | 3/422 1% |
| Non-Cancerous | 3/104 3% | 9/830 1% |
| Other Solid Cancers | 3/94 3% | 17/1515 1% |
| Neuroendocrine Tumour | 4/154 3% | 5/577 1% |
| Bladder Carcinoma | 2/58 3% | 9/956 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 8/810 1% |
| Germ Cell Tumour | 0/25 0% | 2/169 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Head and Neck Carcinoma | 2/85 2% | 10/1574 1% |
| Biliary Tract Carcinoma | 1/54 2% | 6/950 1% |
| Glioma | 2/52 4% | 12/2127 1% |
| Hepatocellular Carcinoma | 0/46 0% | 13/2210 1% |
| Esophageal Carcinoma | 0/23 0% | 4/769 1% |
| Rhabdomyosarcoma | 1/33 3% | 0/171 0% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Kidney Carcinoma | 2/85 2% | 7/1862 0% |
| Ovarian Carcinoma | 3/109 3% | 2/998 0% |
| B-Cell Non-Hodgkins Lymphoma | 3/88 3% | 8/2534 0% |
Mutation Distribution
Where GRM2 is mutated · all tissues, split by cell line vs tissue
How many mutations in GRM2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 899 mutations in GRM2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|